Literature DB >> 8699553

Pharmacokinetics of hydroxocobalamin in smoke inhalation victims.

P Houeto1, S W Borron, P Sandouk, M Imbert, P Levillain, F J Baud.   

Abstract

OBJECTIVE: Hydroxocobalamin has been proposed as a cyanide antidote. Little is known, however, about its pharmacokinetics in human cyanide poisoning.
METHODS: We prospectively studied the pharmacokinetics of hydroxocobalamin in 11 smoke inhalation victims of whom all but one had objective evidence of cyanide exposure. Serum hydroxocobalamin levels were followed from just before drug administration to six days after a single 5 g dose of hydroxocobalamin.
RESULTS: The results (mean +/- standard error) suggest a two compartment model. Distribution half-life is on the order of 1.86 +/- 0.34 h and the elimination half-life 26.2 +/- 2.7 h. The apparent volume of distribution is 0.45 +/- 0.03 L/kg. Renal and total body clearance are 0.31 +/- 0.06 and 0.83 +/- 0.07 L/h, respectively.
CONCLUSION: The apparent volume of distribution suggests a predominantly extracellular partitioning of the antidote, even in the presence of cyanide, an important factor in terms of its antidotal effect. Hydroxocobalamin's elimination half-life in these cyanide-exposed patients far exceeds those found in previous studies of dogs and minimally-exposed humans. If confirmed, this half-life suggests that a single dose of hydroxocobalamin, sufficiently large enough to bind the cyanide present, should be adequate.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8699553     DOI: 10.3109/15563659609013809

Source DB:  PubMed          Journal:  J Toxicol Clin Toxicol        ISSN: 0731-3810


  3 in total

1.  Inhibition of nitric oxide synthase by cobalamins and cobinamides.

Authors:  J Brice Weinberg; Youwei Chen; Ning Jiang; Bethany E Beasley; John C Salerno; Dipak K Ghosh
Journal:  Free Radic Biol Med       Date:  2009-03-27       Impact factor: 7.376

Review 2.  Clinical applications of commonly used contemporary antidotes. A US perspective.

Authors:  C A Bowden; E P Krenzelok
Journal:  Drug Saf       Date:  1997-01       Impact factor: 5.606

Review 3.  Combined methylmalonic acidemia and homocystinuria, cblC type. I. Clinical presentations, diagnosis and management.

Authors:  Nuria Carrillo-Carrasco; Randy J Chandler; Charles P Venditti
Journal:  J Inherit Metab Dis       Date:  2011-07-12       Impact factor: 4.982

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.